Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Urogen Pharma Ltd.
Industry Sector: HealthTechnology
CEO: Elizabeth Barrett, MBA
Number Of Employees: 235
Enterprise Value: $343,793,255
PE Ratio: -3.38
Exchange/Ticker 1: NASDAQ:URGN
Exchange/Ticker 2: N/A
Latest Market Cap: $502,428,992
BioCentury | Jun 21, 2024
Finance
Public Equity Report: Cinclus dips after pricing Stockholm IPO
Plus: Tectonic arrives on NASDAQ; UroGen prices offering amid rolling NMIBC submission
BioCentury | Jun 4, 2024
Management Tracks
New commercial heads for Illumina, UroGen, Invivyd
Plus: Jennifer Fitzpatrick hired as general counsel at Sionna
BioCentury | Jul 27, 2023
Politics, Policy & Law
July 27 Quick Takes: Rachel King out of the running for BIO CEO
Plus: Cross-border oncology play Adlai Nortye launches NASDAQ bid and updates for Lilly’s tirzepatide, Enhertu, Merck’s pneumococcal vaccine, UroGen, Mersana and Biohaven
BioCentury | May 4, 2022
Management Tracks
Hickey returns to U.S. for new role at Pfizer
Plus Kaundinya named president and CEO at GlycoERA, and updates from Plexium, Alentis, ADCendo, Xcell and more
BioCentury | Mar 23, 2022
Management Tracks
Sandrock becomes CEO at Voyager
Plus Faga replaces Suria as Anaptys CEO and updates from Mozart, Longboard, Capsida, Phathom and more
BioCentury | Mar 18, 2022
Finance
Companies dust off alternative funding tools in bear market
A persistent market downturn is driving cash-strapped public biotechs to reach for financing tools little used in recent years
BioCentury | Mar 9, 2022
Finance
March 8 Quick Takes: Blackstone backs DNAnexus with $200M
Plus Sherlock raises $80M and updates from WuXi AppTec, Mustang, UroGen and more
BioCentury | Nov 9, 2021
Management Tracks
Maraganore joins board at Beam
Plus: new CBO, board member at Caribou, Nordic, GT Biopharma and more
BioCentury | Feb 19, 2021
Emerging Company Profile
Primmune: tolerable TLR7 agonists for systemic immune responses
Emerging Company Profile: San Diego-based Primmune is developing oral host-directed antivirals that activate TLR7 signaling
BioCentury | Dec 3, 2020
Management Tracks
Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA
Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) hired Alan Sandler as president, head of global development, oncology, a newly created position. Sandler was SVP and global head of product development oncology
Items per page:
1 - 10 of 31